Sept 1 (Reuters) - U.S. health regulators on Thursday approved a label update to Novartis AG's osteoporosis drug Reclast to warn about the risk of kidney failure associated with the use of the drug.

Novo Nordisk announced on Thursday that a key European Medicines Agency committee has backed a label update for weight-loss drug Ozempic to include the reduction of kidney disease risk. The decision ...

Novo Nordisk drug Ozempic, already a blockbuster seller in type 2 diabetes, now has clinical trial results showing it reduced the risk of kidney disease complications by 24%. The company is planning U ...

(RTTNews) - Novo Nordisk A/S (NVO), Thursday announced that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has supported label update for weight-loss drug ...

Roche is heading to regulators after its blockbuster kidney disease candidate, Gazyva (obinutuzumab), met its primary endpoint during a Phase III trial in membranous nephropathy. In the 104-week, head ...

On Thursday, the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion for an update for Novo Nordisk A/S’ (NYSE:NVO) Ozempic (once-weekly subcutaneous ...

Eli Lilly LLY announced that the FDA has expanded the label of its diabetes drug, Jardiance (empagliflozin), to chronic kidney disease (“CKD”). Jardiance is now approved in the United States to reduce ...